Intermediate-dose immune tolerance induction outperforms with faster success, less bleeding, and no added cost in comparison with low dose: a multicenter randomized clinical trial.
Li Z, Li Z, Cheng X, Zhang H, Yang C, Xu Q, Chen Z, Zhen Y, Li G, Liu G, Yao W, Zhou M, Jin J, Huang J, Fang Y, Xie L, Poon MC, Wu R.
Li Z, et al. Among authors: xie l.
Res Pract Thromb Haemost. 2024 Nov 28;9(1):102639. doi: 10.1016/j.rpth.2024.102639. eCollection 2025 Jan.
Res Pract Thromb Haemost. 2024.
PMID: 39810987
Free PMC article.